SEARCH

SEARCH BY CITATION

References

  • 1
    Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:15723.
  • 2
    Current status of allergen immunotherapy (hyposensiti-sation). Report of a WHO/IUIS working group. Allergy 1989;44:36979.
  • 3
    Current status of allergen immunotherapy. Shortened version of a World Health Organisationhternational Union of Immunological Societies Working Group Report. Lancet 1989;1:25961.
  • 4
    Malling H-J, Weeke B. Immunotherapy. Position Paper of the European Academy of Allergology and Clinical Immunology. Allergy 1993;48 Suppl 14:935.
  • 5
    Bousquet J, Müller UR, Dreborg S, et al. Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergology and Clinical Immunology. Allergy 1987;42: 40113.
  • 6
    Müller U, Mosbech H. Immunotherapy with Hymenoptera venoms. Position paper. Allergy 1993;48 Suppl 14:3746.
  • 7
    International Consensus Report on Diagnosis and Management of Asthma. International Asthma Management Project. Allergy 1992;47:161.
  • 8
    Global strategy for asthma management and prevention. WHO/NHLBI workshop report. In: National Institutes of Health, National Heart, Lung and Blood Institute, Publication no. 95–3659, 1995.
  • 9
    International Consensus Report on Diagnosis and Management of Rhinitis. Allergy 1994;49 Suppl 19:133.
  • 10
    Frew AJ. Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party. BMJ 1993;307: 91923.
  • 11
    Nicklas R, Bernstein I, Blessing-Moore J, et al. Practice parameters for allergen immunotherapy. J Allergy Clin Immunol 1996;6:100111.
  • 12
    Biological products: allergenic extracts: implementation of efficacy review. Federal Register, Food and Drug Administration, 1985;21 CRF Parts 600, 610 and 680 [Docket no. 81N–0096].
  • 13
    Allergen products (Producta allergenica). European Pharmacopeia, 1997:10638.
  • 14
    Dreborg S, Frew A. Allergen standardization and skin tests. EAACI Position paper. Allergy 1993;48 Suppl 14:4982.
  • 15
    The use of standardized allergen extracts. Position Statement. American Academy of Allergy, Asthma, and Immunology (AAAAI). J Allergy Clin Immunol 1997;99: 5836.
  • 16
    Rules governing medicinal products in the European Community. Vol. III. Note for guidance on allergen products. CPMP/BWP/243/96, 1991.
  • 17
    Løwenstein H. Report on behalf of the International Union of Immunological Societies (I.U.I.S.) Allergen Standardization Subcommittee. Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M 1983;78: 418.
  • 18
    Nordic Council on Medicines. Registration of allergen preparations, 2nd Ed. Nordiska Läkemedelsnamnden NLN Publication no. 23, Uppsala, 1989.
  • 19
    Løwenstein H. Report on behalf of the International Union of Immunological Societies (I.U.I.S.) Allergen Standardization Subcommittee. Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M 1983;78: 418.
  • 20
    Gjesing B, Jäger L, Marsh DG, Løwenstein H. The international collaborative study establishing the first international standard for timothy (Phleum pratense) grass pollen allergenic extract. J Allergy Clin Immunol 1985;75:3867.
  • 21
    Larsen JN, Ford A, Gjesing B, et al. The collaborative study of the international standard of dog, Canis domesticus, hair/ dander extract. J Allergy Clin Immunol 1988;82:31830.
  • 22
    Helm RM, Gauerke MB, Baer H, et al. Production and testing of an international reference standard of short ragweed pollen extract. J Allergy Clin Immunol 1984;73:790800.
  • 23
    Helm RM, Squillace DL, Aukrust L, et al. Production of an international reference standard Alternaria extract. I. Testing of candidate extracts. Int Arch Allergy Appl Immunol 1987;82: 17889.
  • 24
    Platts-Mills TAE, Chapman MD. Allergen standardization. J Allergy Clin Immunol 1991;87:6215.
  • 25
    Norman PS. WHO-IUIS International Standards: advantages of these extracts Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994;87: 5964.
  • 26
    Mohapatra SS. Recombinant allergens and allergen standardization. J Allergy Clin Immunol 1992;89:9212.
  • 27
    Kraft D, Sehon A. Molecular biology and immunology of allergens. Boca Raton, FL CRC Press, 1992.
  • 28
    Bousquet J. Clinical use of recombinant allergens and epitopes. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994;87:25762.
  • 29
    Turkeltaub PC, Rastogi SC, Baer H, Anderson MC, Norman PS. A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose-response curve and effect of wheal, erythema, and patient selection on assay results. J Allergy Clin Immunol 1982;70:134352.
  • 30
    Bousquet J, Guerin B, Michel FB. Units of allergen extracts. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1992;85:10516.
  • 31
    Gleich G, Larson J, Jones R, Baer H. Measurement of the potency of allergy extracts by their inhibitory capacities in the radioallergosorbent test. J Allergy Clin Allergol 1974;53:115869.
  • 32
    Maasch HJ, Wihl J Å, Schultze-Werninghaus G, Geissler W, Wahl R. A manufacturer's criteria for in-house reference preparations for RAST inhibition. Ann Allergy 1987;59:2933.
  • 33
    Liu DT. Regulation of allergenic products in the U.S.A.: CBER initiatives. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994;87: 812.
  • 34
    Bousquet J, Michel F. Standardization of allergens. In: SpectorS, editor. Provocation testing in clinical practice. New York: Marcel Dekker, 1994: 1550.
  • 35
    Scheiner O, Kraft D. Basic and practical aspects of recombinant allergens. Allergy 1995;50:38492.
  • 36
    Chapman M. Monoclonal antibody immunoassays: quantitative methods for allergen standardization. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994;87:1204.
  • 37
    Van Ree R. Analytical aspects of standardization of allergenic extracts. Allergy 1997;52:795806.
  • 38
    Allergen nomenclature. WHO/IUS Allergen Nomenclature Subcommittee World Health Organization, Geneva, Switzerland. Clin Exp Allergy 1995;25:2737.
  • 39
    King TP, Hoffman D, Løwenstein H, Marsh DG, Platts-Mills TA, Thomas W. Allergen nomenclature. Allergy 1995;50:76574.
  • 40
    Carreira J, Lombardero M, Ventas P. New developments in in vitro methods Quantification of clinically relevant allergens in mass units Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frank A M 1994;87: 15564.
  • 41
    Dreborg S, Einarsson R. The major allergen content of allergenic preparations reflects their biological activity. Allergy 1992;47:41823.
  • 42
    Yasueda H. Okuda M, Yoshida H, et al. A basic policy for allergen standardization in our country and standardization of Japanese cedar (Crypromeria japonica) pollen extracts. Allergen Committee in Japanese Society of Allergology. Allergol Int 1997;in press.
  • 43
    Steinberger P, Kraft D, Valenta R. Construction of a combinatorial IgE library from an allergic patient. Isolation and characterization of human IgE Fabs with specificity for the major timothy grass pollen allergen, Phl p 5. J Biol Chem 1996;271: 1096772.
  • 44
    Norman PS. International units. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1988;82:459.
  • 45
    Turkeltaub PC. Use of skin testing for evaluation of potency, composition, and stability of allergenic products. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994;87:7987.
  • 46
    Methods of Allergenic Products Testing Laboratory. CBER FDA Docket no. 94N–0012 1993.
  • 47
    Reisrnan RE, Arbesman CE, Laze M. Clinical and immunological studies of venom immunotherapy. Clin Allergy 1979;9:16774.
  • 48
    Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:15761.
  • 49
    Yunginger JW, Paull BR, Jones RT, Santrach PJ. Rush venom immunotherapy program for honeybee sting sensitivity. J Allergy Clin Immunol 1979;63:3407.
  • 50
    Bousquet J, Calvayrac P, Guerin B, et al. Immunotherapy with -a standardized Dermatophagoides pteronyssinas extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985;76: 73444.
  • 51
    Bousquet J, Hejjaoui A, Skassa-Brociek W, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol 1987;80: 5918.
  • 52
    Hedlin G, Graff-Lonnevig V, Heilborn H, et al. Immuno-therapy with cat- and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study. J Allergy Clin Immunol 1986;77: 48896.
  • 53
    Kordash TR, Amend MJ, Freshwater LL, Baker RE. In vivo and in vitro characterization of Allpyral grass pollen extracts. Ann Allergy 1994;73:12733.
  • 54
    Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978;2:91215.
  • 55
    Blainey A, Phillips M, Ollier S, Davies R. Hyposensitization with a tyrosine adsorbed extract of Dermntophagoides pteronyssinus in adults with perennial allergic rhinitis. Allergy 1984;39:5218.
  • 56
    Genin I, Barratt G, Tran XT, Delattre J, Puisieux F. Optimization and characterization of freeze-dried multi-lamellar liposomes incorporating different standardized allergen extracts. Allergy 1994;49:64552.
  • 57
    Walls AF. Liposomes for allergy immunotherapy Clin Exp Allergy 1992;22:12.
  • 58
    Marsh DG, Norman PS, Roebber M, Lichtenstein LM. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J Allergy Clin Imrnunol 1981;68: 44959.
  • 59
    Bousquet J, Maasch HJ, Hejjaoui A, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinocon-junctivitis and asthma. J Allergy Clin Immunol 1989;81: 54656.
  • 60
    Grammer LC, Shaughnessy MA, Patterson R. Modified forms of allergen immunotherapy. J Allergy Clin Immunol 1985;76:397401.
  • 61
    Corrado OJ, Pastorello E, Ollier S, et al. A double-blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac) in patients with perennial rhinitis. I. Clinical aspects Allergy 1989;44: 10815.
  • 62
    Bousquet J, Michel FB. Safety considerations in assessing the role of immunotherapy in allergic disorders Drug Saf 1994;10: 517.
  • 63
    Juniper EF, Roberts RS, Kennedy LK, et al. Polyethylene glycol-modified ragweed pollen extract in rhinocon-junctivitis. J Allergy Clin Immunol 1985;75:57885.
  • 64
    Juniper EF, O'Connor J, Roberts RS, Evans S, Hargreave FE, Dolovich J. Polyethylene glycol-modified ragweed extract: comparison of two treatment regimens. J Allergy Clin Immunol 1986;78:8516.
  • 65
    Müller U, Rabson AR, Bischof M, Lomnitzer R, Dreborg S, Lanner A. A double-blind study comparing monomethoxy polyethylene glycol-modified honeybee venom and unmodified honeybee venom for immunotherapy. I. Clinical results. J Allergy Clin Immunol 1987;80: 25261.
  • 66
    Dreborg S, Akerblom EB. Immunotherapy with mono-methoxypolyethylene glycol modified allergens Crit Rev Ther Drug Carrier Syst 1990;6: 31565.
  • 67
    Mosbech H, Dreborg S, Frolund L, et al. Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. I. Clinical effect evaluated by diary cards and a retrospective assessment. Allergy 1989;44: 48798.
  • 68
    Cockcroft D, Cuff M, Tarlo S, Dolovich J, Hargreave F. Allergen-injection therapy with glutaraldehyde-modified-ragweed pollen-tyrosine adsorbate. A double-blind trial. J Allergy Clin Immunol 1977;60: 5662.
  • 69
    Miller A. A trial of hyposensitization in 1974/5 in the treatment of hay fever using a glutaraldehyde-pollen-tyrosine adsorbate. Clin Allergy 1979;6:55761.
  • 70
    Juniper EF, Kline PA, Ramsdale EH, Hargreave FE. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis J Allergy Clin Immunol 1990;85: 60611.
  • 71
    Nelson HS. Effect of preservatives and conditions of storage on the potency of allergy extracts J Allergy Clin Immunol 1981;67: 649.
  • 72
    Nelson HS, Ikle D, Buchmeier A. Studies of allergen extract stability: the effects of dilution and mixing. J Allergy Clin Immunol 1996;98:3828.
  • 73
    Esch RE. Role of proteases on the stability of allergenic extracts Arb Paul Ehrlich Inst Bundesamt Sera lmpfstoffe Frankf A M 1992;85: 1717.
  • 74
    Kordash TR, Amend MJ, Williamson SL, Jones JK, Plunkett GA. Effect of mixing allergenic extracts containing Helminthosporiurn, D. farinae, and cockroach with perennial ryegrass. Ann Allergy 1993;71: 2406.
  • 75
    Frostad AB, Grimmer O, Sandvik L, Moxnes A, Aas K. Clinical effects of hyposensitization using a purified allergen preparation from timothy pollen as compared to crude aqueous extracts from timothy pollen and a four-grass pollen mixture respectively. Clin Allergy 1983;13:33757.
  • 76
    Møller C, Dreborg S. Cross-reactivity between deciduous trees during immunotherapy. I. In vivo results Clin Allergy 1986;16: 13543.
  • 77
    Wihl JÅ, Ipsen H, Petersen BN, Munch EP, Janniche H, Løwenstein H. Immunotherapy with partially purified and standardized tree pollen extracts. II. Results of skin prick tests and nasal provocation tests from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988;43: 3639.
  • 78
    Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:14573.
  • 79
    Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science 1997; 275: 779.
  • 80
    Pene J, Rousset F, Briere F, et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2, Proc Natl Acad Sci U S A 1988;85: 68804.
  • 81
    Del Prete G, Maggi E, Parronchi P, et al. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J Immunol 1988;140:41938.
  • 82
    de Vries JE, Zurawski G. Immunoregulatory properties of IL-13: its potential role in atopic disease. Int Arch Allergy Immunol 1995;106:1759.
  • 83
    Yssel H, Fasler S, de Vries JE, de Waal-Malefyt R. IL-12 transiently induces IFN-gamma transcription and protein synthesis in human CD4+ allergen-specific Th2 T cell clones Int Immunol 1994;6: 10916.
  • 84
    Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988;167:21924.
  • 85
    Lichtenstein L, Ishizaka K, Norman P, Sobotka A, Hill B. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973;52: 47282.
  • 86
    Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982;70:26171.
  • 87
    Malling H-J, Skov PS, Permin H, Norn S, Weeke B. Basophil histamine release and humoral changes during immunotherapy. Dissociation between basophil-bound specific IgE, serum value, and cell sensitivity. Allergy 1982;37: 18790.
  • 88
    MacDonald SM, Rafnar T, Langdon J, Lichtenstein LM. Molecular identification of an IgE-dependent histamine-releasing factor. Science 1995;269:68890.
  • 89
    Saxon A, Max EE, Diaz-Sanchez D, Zhang K. Alternative RNA of epsilon transcripts produces mRNAs encoding two membrane and four secreted IgE isoforms. Int Arch Allergy Immunol 1995;107:457.
  • 90
    Van der Zee JS, Aalberse RC. The role of IgG in immediate-type hypersensitivity. Eur Respir J Suppl 1991;13:91s6.
  • 91
    Kaneko M, Swanson MC, Gleich GJ, Kita H. Allergen-specific IgGl and IgG3 through Fc gamma RII induce eosinophil degranulation. J Clin Invest 1995;95:281321.
  • 92
    Leynadier F, Abuaf N, Halpern GM, Murrieta M, Garcia-Duarte C, Dry J. Blocking IgG antibodies after rush immunotherapy with mites. Ann Allergy 1986;57:3259.
  • 93
    Witteman AM, Stapel SO, Sjamsoedin DH, Jansen HM, Aalberse RC, van der Zee JS. Fel d 1-specific IgG antibodies induced by natural exposure have blocking activity in skin tests. Int Arch Allergy Immunol 1996;109:36975.
  • 94
    Star M, Weinstock M. Studies in pollen allergy. III. The relationship between blocking antibody levels, and symptomatic relief following hyposensitization with Allpyral in hay fever subjects. Int Arch Allergy 1970;38: 51421.
  • 95
    Golden DB, Meyers DA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J Allergy Clin Immunol 1982;69:48993.
  • 96
    Visco V, Dolecek C, Denepoux S, et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J Immunol 1996;157:95662.
  • 97
    Djurup R, Østerballe O. IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Prognostic value of serum IgG subclass antibody levels early in immunotherapy. Allergy 1984;39: 43341.
  • 98
    Bousquet J, Maasch H, Martinot B, Hejjaoui A, Wahl R, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988;82: 43946.
  • 99
    Müller U, Helbling A, Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honeybee venom. Allergy 1989;44:41218.
  • 100
    Reisman RE. Should routine measurements of serum venom-specific IgG be a standard of practice in patients receiving venom immunotherapy? [editorial; comment]. J Allergy Clin Immunol 1992;90:2824.
  • 101
    Golden DB, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996;97:57987.
  • 102
    Djurup R, Malling H-J. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy 1987;17:45968.
  • 103
    Ito K, Kudo K, Okudaira H, et al. IgGl antibodies to house dust mite (Dermatophagoides farinae) and late asthmatic response. Int Arch Allergy Appl Immunol 1986;81:6974.
  • 104
    Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M. Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy 1991; 21: 11519.
  • 105
    Hedlin G, Silber G, Naclerio R, et al. Comparison of the in vivo and in vitro response to ragweed immunotherapy in children and adults with ragweed-induced rhinitis. Clin Exp Allergy 1990;20:491500.
  • 106
    Durham S, Varney V, Gaga M, Jacobson M, Frew A, Kay A. Grass pollen immunotherapy decreases mast cell numbers in the skin. Proc Am Assoc Phys 1997;submitted.
  • 107
    Bousquet J, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts J Allergy Clin Immunol 1991;88: 4353.
  • 108
    Creticos PS, Adkinson N Jr, Kagey-Sobotka A, et al. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest 1985;76: 224753.
  • 109
    Furin MJ, Norman PS, Creticos PS, et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 1991;88:2732.
  • 110
    Iliopoulos O, Proud D, Adkinson N Jr, et al. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol 1991;87:85566.
  • 11
    Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988;82:47080.
  • 12
    Jutel M, Muller U, Fricker M, Rihs S, Pichler W, Dahinden C. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils Clin Exp Immunol 1996;12: 111218.
  • 13
    Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996;51: 4304.
  • 114
    Durham S, Varney V, Gaga M, Frew A, Jacobson M, Kay A. Grass pollen immunotherapy remains effective 3 years after discontinuation: a double-blind, placebo-controlled withdrawal study. Clin Exp Allergy 1998; in press.
  • 115
    Durham S, Varney V, Gaga M, Frew A, Jacobson M, Kay A. Immunotherapy and allergic inflammation. Clin Exp Allergy 1991;21 Suppl 1:20610.
  • 116
    Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cyto-kine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:64451.
  • 117
    Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97:135665.
  • 118
    Hamid Q, Schotman E, Jacobson M, Walker S, Durham S. Increases in interleukin-12 (IL-12) messenger RNA+ (mRNA+) cells accompany inhibition of allergen induced late skin responses following successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99:25460.
  • 119
    Renz H, Lack G, Saloga J, et al. Inhibition of IgE production and normalization of airways responsiveness by sensitized CD8 T cells in a mouse model of allergen-induced sensitization. J Immunol 1994;152:35160.
  • 120
    Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Müller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:418794.
  • 121
    Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:212330.
  • 122
    McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995;25:82838.
  • 123
    Secrist H, DeKruyff RH, Umetsu DT. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995;181:10819.
  • 124
    Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983;157:143447.
  • 125
    Fasler S, Aversa G, Terr A, Thestrup-Pedersen K, de Vries JE, Yssel H. Peptide-induced anergy in allergen-specific human Th2 cells results in lack of cytokine production and B cell help for IgE synthesis. Reversal by IL-2, not by IL-4 or IL-13. J Immunol 1995;155: 41994206.
  • 126
    Tsicopoulos A, Labalette M, Akoum H, et al. CD28 expression is increased in venom allergic patients but is not modified by specific immunotherapy. Clin Exp Allergy 1996;12:111925.
  • 127
    Akdis CA, Akdis M, Blesken T, et al. Epitope-specific T cell tolerance to phospholipase A, in bee venom immunotherapy and recovery by IL-3 and IL-15 in vitro. J Clin Invest 1996;98:167683.
  • 128
    Østerballe O. Immunotherapy in hay fever with two major allergens 19, 25 and partially purified extract of timothy grass pollen. A controlled double blind study. In vivo variables, season I. Allergy 1980;35: 47389.
  • 129
    Norman P, Winkenwerder W, Lichtenstein L. Immunotherapy of hay fever with ragweed antigen E: comparisons with whole extracts and placebo. J Allergy 1968;42:93108.
  • 130
    Reisman RE, Wicher K, Arbesman CE. Immunotherapy with antigen E. J Allergy 1969;44:8295.
  • 131
    Van Metre TE, Adkinson N Jr, Lichtenstein LM, et al. A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980;65:28897.
  • 132
    Hirsch SR, Kalbfleisch JH, Golbert TM, et al. Rinkel injection therapy: a multicenter controlled study. J Allergy Clin Immunol 1981;68:13355.
  • 133
    Hirsch SR, Kalbfleisch JH, Cohen SH. Comparison of Rinkel injection therapy with standard immunotherapy. J Allergy Clin Immunol 1982;70:18390.
  • 134
    Bousquet J, Des Roches A, Paradis L, Dhivert H, Michel FB. Specific immunotherapy in house dust mite allergy. Clin Rev Allergy Immunol 1995;13:1519.
  • 135
    Turkeltaub PC, Campbell G, Mosimann JE. Comparative safety and efficacy of short ragweed extracts differing in potency and composition in the treatment of fall hay fever. Use of allergenically bioequivalent doses by parallel line bioassay to evaluate comparative safety and efficacy. Allergy 1990;45: 52846.
  • 136
    Creticos PS, Van Metre TE, Mardiney MR, Rosenberg GL, Norman PS, Adkinson N Jr Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984;73:94104.
  • 137
    Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91:70922.
  • 138
    Wahn U, Schweter C, Lind P, Lowenstein H. Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies. J Allergy Clin Immunol 1988;82:36070.
  • 139
    Bousquet J, Michel E Specific immunotherapy in allergic rhinitis and asthma. In: BusseW, HolgateS, editors. Asthma and rhinitis. Oxford: Blackwell Scientific, 1995: 130924.
  • 140
    Taylor WW, Ohman J Jr, Lowell FC. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of bronchial responses to cat allergen and histamine. J Allergy Clin Immunol 1978;61: 2837.
  • 141
    Ohman J Jr, Findlay SR, Leitermann KM. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol 1984;74: 2309.
  • 142
    Sundin B, Lilja G, Graff-Lonnevig V, et al. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986;77: 47887.
  • 143
    Haugaard L, Dahl R. Immunotherapy in patients allergic to cat and dog dander. I. Clinical results. Allergy 1992;47: 24954.
  • 144
    Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994;93:55666.
  • 135
    Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334:5016.
  • 146
    Hunt KJ, Sobotka AK, Valentine MD, Yunginger JW, Lichtenstein LM. Sensitization following Hymenoptera whole body extract therapy. J Allergy Clin Immunol 1978;61:4853.
  • 147
    Müller U, Thurnheer U, Patrizzi R, Spiess J, Hoigne R. Immunotherapy in bee sting hypersensitivity. Bee venom versus whole-body extract. Allergy 1979;34: 36978.
  • 148
    Doh I, Martinez-Cócera C, Bartolomé JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996;51:489500.
  • 149
    Van Bever HP, Stevens WJ. Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy. J Allergy Clin Immunol 1990;86:1416.
  • 150
    Lichtenstein L, Norman P, Winkenwerder L. A single year of immunotherapy in ragweed hay fever. Am J Med 1971;44:51424.
  • 151
    Norman PS, Lichtenstein LM. The clinical and immunologic specificity of immunotherapy. J Allergy Clin Immunol 1978;61:3707.
  • 152
    Bousquet J, Hejjaoui A, Michel FB. Specific immunotherapy in asthma. J Allergy Clin Immunol 1990;86:292305.
  • 153
    Bousquet J, Chanez P, Lacoste JY, et al. Asthma: a disease remodeling the airways. Allergy 1992;47:311.
  • 154
    Des Roches A, Paradis L, Ménardo J-L, Bouges S, Daurès J-P, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensi-tizations in children. J Allergy Clin Immunol 1997;99: 4503.
  • 155
    Gillman SA, Cummins LH, Kozak P Jr, Hoffman DR. Venom immunotherapy: comparison of “rush” vs “conventional” schedules. Ann Allergy 1980;45:3514.
  • 156
    Golden DB, Kagey-Sobotka A, Valentine MD, Lichten-stein LM. Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981;67:3704.
  • 157
    Mosbech H, Malling H-J, Biering I, et al. Immunotherapy with yellow jacket venom. A comparative study including three different extracts, one adsorbed to aluminium hydroxide and two unmodified. Allergy 1986;41: 95103.
  • 158
    Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:52935.
  • 159
    Müller U, Berchtold E, Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol 1991;87:7029.
  • 160
    Tarhini H, Knani J, Michel FB, Bousquet J. Safety of venom immunotherapy administered by a cluster schedule. J Allergy Clin Immunol 1992;89:11989.
  • 161
    Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993;23:22630.
  • 162
    Van der Zwan JC, Flinterman J, Jankowski IG, Kerckhaert JA. Hyposensitisation to wasp venom in six hours. BMJ 1983;287:132931.
  • 163
    Bousquet J, Fontez A, Aznar R, Robinet-Levy M, Michel FB. Combination of passive and active immunization in honeybee venom immunotherapy. J Allergy Clin Immunol 1987;79:94754.
  • 164
    Golden DB, Kagey-Sobotka A, Valentine MD, Lichten-stein LM. Prolonged maintenance interval in Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981;67:4824.
  • 165
    Bousquet J, Knani J, Velasquez G, Menardo JL, Guilloux L, Michel FB. Evolution of sensitivity to Hymenoptera venom in 200 allergic patients followed for up to 3 years. J Allergy Clin Immunol 1989;84:94450.
  • 166
    Reisman RE. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis J Allergy Clin Immunol 1993;92: 8316.
  • 167
    Bousquet J, Michel F. Immunotherapy in rhinitis. In: MygindN, NaclerioR, editors. Allergic and non-allergic rhinitis; clinical aspects. Copenhagen: Munksgaard, 1992: 13648.
  • 168
    Bousquet J, Hejjaoui A, Soussana M, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight aller-goid. J Allergy Clin Immunol 1990;85: 4907.
  • 169
    Frankland A, Augustin R. Prophylaxis of summer hay fever and asthma: a controlled trial comparing crude grass pollen extract with the isolated main protein components. Lancet 1954;1:10558.
  • 170
    Grammer LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R. A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy. J Allergy Clin Immunol 1983;72:44853.
  • 171
    Grammer LC, Shaughnessy MA, Finkle SM, Shaughnessy JJ, Patterson R. A double-blind placebo-controlled trial of polymerized whole grass administered in an accelerated dosage schedule for immunotherapy of grass pollinosis. J Allergy Clin Imrnunol 1986;78:11804.
  • 172
    McAllen M. Hyposensitization in grass pollen hay fever. Acta Allergol 1969;24:42131.
  • 173
    Machiels JJ, Buche M, Somville MA, Jacquemin MG, Saint-Remy JM. Complexes of grass pollen allergens and specific antibodies reduce allergic symptoms and inhibit the seasonal increase of IgE antibody. Clin Exp Allergy 1990;20:65360.
  • 174
    Machiels JJ, Somville MA, Jacquemin MG, Saint-Remy JM. Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergen-antibody complex immunotherapy. Allergy 1991;46: 33548.
  • 175
    Ortolani C, Pastorello E, Moss RB, et al. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol 1984;73:28390.
  • 176
    Pastorello EA, Pravettoni V, Incorvaia C, et al. Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever. Allergy 1992;47:28190.
  • 177
    Starr M, Weinstock M. Studies in pollen allergy. III. The relationship between blocking antibody levels, and symptomatic relief following hyposensitization with Allpyral in hay fever subjects. Int Arch Allergy 1970;38: 51421.
  • 178
    Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:2659.
  • 179
    Weyer A, Donat N, L'Heritier C, et al. Grass pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and methodological aspects of a pre-seasonal course of desensitization with a four-grass pollen extract. Allergy 1981;36: 30917.
  • 180
    Arbesman CE, Reisman RE. Hyposensitization therapy including repository: a double-blind study. J Allergy 1964;35:1217.
  • 181
    Grammer LC, Zeiss CR, Suszko IM, Shaughnessy MA, Patterson R. A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy. J Allergy Clin Immunol 1982;69:4949.
  • 182
    Lichtenstein L, Norman P, Winkenwerder W. Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. Am J Med 1968;44:51424.
  • 183
    Lowell F, Franklin W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med 1965;273:6759.
  • 184
    Meriney DK, Kothari H, Chinoy P, Grieco MH. The clinical and immunologic efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever. Ann Allergy 1986;56:348.
  • 185
    Van Metre TE, Adkinson N Jr, Amodio FJ, et al. A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980;66:50013.
  • 186
    Van Metre TE, Adkinson N Jr, Amodio FJ, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982;69:18193.
  • 187
    Norman PS, Lichtenstein LM. Comparisons of alum-precipitated and unprecipitated aqueous ragweed pollen extracts in the treatment of hay fever. J Allergy Clin Immunol 1978;61:3849.
  • 88
    Norman PS, Lichtenstein LM, Kagey-Sobotka A, Marsh DG. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J Allergy Clin Immunol 1982;70:24860.
  • 189
    D'Amato G, Kordash TR, Liccardi G, Lobefalo G, Cazzola M, Freshwater LL. Immunotherapy with Alpare in patients with respiratory allergy to Parieraria pollen: a two year double-blind placebo-controlled study. Clin Exp Allergy 1995;25:14958.
  • 190
    Ortolani C, Pastorello EA, Incorvaia C, et al. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria juduica in patients with Parietaria hay fever. Allergy 1994;49:1321.
  • 191
    Pence H, Mitchell D, Greenly R, Updegraft B, Selfridge H. Immunotherapy for mountain cedar pollinosis. A double-blind controlled study. J Allergy Clin Immunol 1976;58: 3950.
  • 192
    Karmakar PR, Das A, Chatterjee BP. Placebo-controlled immunotherapy with Cocos nucifera pollen extract. Int Arch Allergy Immunol 1994;103:194201.
  • 193
    Cantani A, Businco E, Benincori N, de Angelis M, di Fazio A, Businco L. A three year controlled study in children with pollinosis treated with immunotherapy. Ann Allergy 1984;53:7984.
  • 194
    Norman P, Winkenwerder W, Lichtenstein L. Maintenance immunotherapy in ragweed hay fever. Booster injections at six week intervals. J Allergy 1971;47: 27382.
  • 195
    Citron K, Frankland A, Sinclair J. Inhalation tests of bronchial hypersensitivity in pollen asthma. Thorax 1958;13:22932.
  • 196
    Armentia-Medina A, Blanco-Quiros A, Martin-Santos JM, et al. Rush immunotherapy with a standardized Bermuda grass pollen extract. Ann Allergy 1989;63:12735.
  • 197
    Rak S, Hakånsson L, Venge F. Eosinophil chemotactic activity in allergic patients during the birch pollen season: the effect of immunotherapy. Int Arch Allergy Appl Immunol 1987;82:34950.
  • 198
    Reid MJ, Moss RB, Hsu YP, Kwasnicki JM, Commerford TM, Nelson BL. Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. J Allergy Clin Immunol 1986;78:590600.
  • 199
    Bruce C, Norman P, Rosenthal R, Lichtenstein L. The role of ragweed pollen in autumnal asthma. J Allergy Clin Immunol 1977;59:44959.
  • 200
    Hill DJ, Hosking CS, Shelton MJ, Turner MW. Failure of hyposensitisation in treatment of children with grass-pollen asthma. BMJ 1982;284:3069.
  • 201
    Bousquet J, Hejjaoui A, Becker WM, et al. Clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. I. Clinical and immunologic characteristics. J Allergy Clin Immunol 1991;87: 73746.
  • 202
    Phe J, Rivier A, Lagier B, Becker WM, Michel FB, Bousquet J. Differences in IL-4 release by PBMC are related with heterogeneity of atopy. Immunology 1994;81:5864.
  • 203
    Eriksson NE, Wihl JÅ, Arrendal H, Strandhede SO. Tree pollen allergy. III. Cross reactions based on results from skin prick tests and the RAST in hay fever patients. A multi-centre study. Allergy 1987;42: 20514.
  • 204
    Hirschwehr R, Valenta R, Ebner C, et al. Identification of common allergenic structures in hazel pollen and hazelnuts: a possible explanation for sensitivity to hazelnuts in patients allergic to tree pollen. J Allergy Clin Immunol 1992;90:92736.
  • 205
    Ebner C, Hirschwehr R, Bauer L, et al. Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin). J Allergy Clin Immunol 1995;95:9629.
  • 206
    Pauli G, Bessot JC, Dietemann-Molard A, Braun PA, Thierry R. Celery sensitivity: clinical and immunological correlations with pollen allergy. Clin Allergy 1985;15:2739.
  • 207
    Bernhisel-Broadbent I Allergenic cross-reactivity of foods and characterization of food allergens and extracts. Ann Allergy Asthma Immunol 1995;75:295303.
  • 208
    Moller C. Effect of pollen immunotherapy on food hyper sensitivity in children with birch pollinosis. AM Allergy 1989;62:3435.
  • 209
    Kelso JM, Jones RT, Tellez R, Yunginger JW. Oral allergy syndrome successfully treated with pollen immunotherapy. Ann Allergy Asthma Immunol 1995;74:3916.
  • 210
    Bousquet J, Michel FB. Specific immunotherapy in asthma: is it effective J Allergy Clin Immunol 1994;94:111.
  • 211
    Mc Allen M, Assem E, Maunsell K. House-dust mite asthma. Results of challenge tests on five criteria with Dermatophagoides pteronyssinus. BMJ 1970;2: 5014.
  • 212
    Machiels JJ, Somville MA, Lebrun PM, Lebecque SJ, Jacquemin MG, Saint-Remy JM. Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes. J Clin Invest 1990;85:102435.
  • 213
    Van Bever HP, Stevens WJ. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus). Eur Respir J 1992;5:31822.
  • 214
    Garcia-Ortega P, Merelo A, Marrugat J, Richart C. Decrease of skin and bronchial sensitization following short-intensive scheduled immunotherapy in mite-allergic asthma. Chest 1993;103:1837.
  • 215
    Mosbech H, Dreborg S, Frolund L, et al. Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. II. Effect evaluated by challenges with allergen and histamine. Allergy 1989;44: 499509.
  • 216
    D'Souza M, Pepys J, Wells I, et al. Hyposensitization with Dermatophagoides pteronyssinus in house dust allergy: a controlled study of clinical and immunological effects. Clin Allergy 1973;3:17793.
  • 217
    Gabriel M, Ng H, Allan W, Hill L, Nunn A. Study of prolonged hyposensitization with D. pteronyssinus extract in allergic rhinitis. Clin Allergy 1977;7: 32536.
  • 218
    Amaral-Marques R, Avila R. Results of a clinical trial with a Dermatophagoides pteronyssinus tyrosine adsorbed vaccine. Allergol Immunopathol (Madr) 1978;6:2315.
  • 219
    Franco C, Barbadori S, Freshwater LL, Kordash TR. A double-blind, placebo controlled study of Alpare mite. D. pteronyssinus immunotherapy in asthmatic patients. Allergol Immunopathol (Madr) 1995;23: 5866.
  • 220
    Olsen OT, Larsen KR, Jacobsen L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997;52:8539.
  • 221
    Pichler CE, Marquardsen A, Sparholt S, et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreac-tivity. Allergy 1997;52: 27483.
  • 222
    Gaddie J, Skinner C, Palmer K. Hyposensitization with house dust mite vaccine in bronchial asthma. BMJ 1976;2:5612.
  • 223
    Pauli G, Bessot JC, Bigot H, et al. Clinical and immunologic evaluation of tyrosine-adsorbed Dermatophagoides pteronyssinus extract: a double-blind placebo-controlled trial. J Allergy Clin Immunol 1984;74:52435.
  • 224
    Newton D, Maberley D, Wilson R. House dust mite hyposensitization. Br J Dis Chest 1978;72:218.
  • 225
    Armentia-Medina A, Tapias JA, Martin JF, Ventas F, Fernandez A. Immunotherapy with the storage mite Lepidoglyphus destructor. Allergol Immunopathol (Madr) 1995;23:21123.
  • 226
    Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immuno-therapy. J Allergy Clin Immunol 1988;82: 9717.
  • 227
    McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990;86:52131.
  • 228
    Ewan PW, Alexander MM, Snape C, Ind PW, Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy 1988;18:5018.
  • 229
    Pastorello EA, Ortolani C, Incorvaia C, et al. A double-blind study of hyposensitization with an alginate-conjugated extract of Dermatophagoides pteronyssinus (Conjuvac) in patients with perennial rhinitis. II. Immuno-logical aspects. Allergy 1990;45: 50514.
  • 230
    Löfkvist T, Agrell B, Dreborg S, Svensson G. Effects of immunotherapy with a purified standardized allergen preparation of Dermatophagoides farinae in adults with perennial allergic rhinoconjunctivitis. Allergy 1994;49:1007.
  • 231
    Bertelsen A, Andersen JB, Christensen J, Ingemann L, Kristensen T, Østergaard PA. Immunotherapy with dog and cat extracts in children. Allergy 1989;44:3305.
  • 232
    Bucur J, Dreborg S, Einarsson R, Ljungstedt-Pahhan I, Nilsson JE, Persson G. Immunotherapy with dog and cat allergen preparations in dog-sensitive and cat-sensitive asthmatics. Ann Allergy 1989;62:35561.
  • 233
    Hedlin G, Graff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991;87: 95564.
  • 234
    Lilja G, Sundin B, Graff-Lonnevig V, et al. Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment. J Allergy Clin Immunol 1989;83: 3744.
  • 235
    Rohatgi N, Dunn K, Chai H. Cat- or dog-induced immediate and late asthmatic responses before and after immunotherapy. J Allergy Clin Immunol 1988;82:38997.
  • 236
    Valovirta E, Viander M, Koivikko A, Vanto T, Ingeman L. Immunotherapy in allergy to dog. Immunologic and clinical findings of a double-blind study. Ann Allergy 1986;57: 1739.
  • 237
    Valovirta E, Koivikko A, Vanto T, Viander M, Ingeman L. Irnmunotherapy in allergy to dog: a double-blind clinical study. Ann Allergy 1984;53:858.
  • 238
    Van Metre TE, Marsh DG, Adkinson N Jr, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol 1988;82:105568.
  • 239
    Salvaggio J, Aukrust L. Postgraduate course presentations. Mold-induced asthma. J Allergy Clin Immunol 1981;68: 32746.
  • 240
    Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990;85:46072.
  • 241
    Malling H-J, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarurn. Allergy 1986;41: 50719.
  • 242
    Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporiurn herbarurn preparation. I. Clinical results. Allergy 1986;41: 13140.
  • 243
    Allergenic extracts made from bacteria. Federal Register, 42 FR 58266, 44 FR 1544, 1979.
  • 244
    Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995;311:96974.
  • 245
    Adkinson NF Jr, Eggleston P, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336:32431.
  • 246
    Mosbech H, Østerballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988;43:15239.
  • 247
    Jacobsen L, Nuchel Petersen B, Wihl JÅ, Løwenstein H, Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997;52: 91420.
  • 248
    Grammer LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Immunol 1984;73:4849.
  • 249
    Norman PS, Creticos PS, Marsh DG. Frequency of booster injections of allergoids. J Allergy Clin Immunol 1990;85:8894.
  • 250
    Ebner C, Kraft D, Ebner H. Booster immunotherapy (BIT). Allergy 1994;49:3842.
  • 251
    Price JF, Warner JO, Hey EN, Turner MW, Soothill JF. A controlled trial of hyposensitization with adsorbed tyro-sine Derrnatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects. Clin Allergy 1984;14:20919.
  • 252
    Hedlin G, Heilborn H, Lilja G, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995;96:87985.
  • 253
    Yeung M, O'Connor SA, Parry DT, Cochrane GM. Compliance with prescribed drug therapy in asthma. Respir Med 1994;88:315.
  • 254
    Weinstein AG. Strategies to improve drug compliance in children. Del Med J 1981;53:13942.
  • 255
    Thomas EJ, Burstin HR, O'Neil AC, Orav EJ, Brennan TA. Patient noncompliance with medical advice after the emergency department visit. Ann Emerg Med 1996;27:4955.
  • 256
    Pedersen S. Ensuring compliance in children. Eur Respir J 1992;5:1435.
  • 257
    Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993;91:7347.
  • 258
    Lower T, Henry J, Mandik L, Janosky J, Friday G Jr Compliance with allergen immunotherapy. Ann Allergy 1993;70:4802.
  • 259
    Rudd S. Immunotherapy compliance - a shot in the dark. Ann Allergy Asthma Immunol 1995;74:1958.
  • 260
    Tinkelman D, Smith F, Cole WR, Silk HJ. Compliance with an allergen immunotherapy regime. Ann Allergy Asthma Immunol 1995;74:2416.
  • 261
    Frost L, Johansen F, Pedersen S, Veien N, Østergaard PA, Nielsen MH. Persistent subcutaneous nodules in children hyposensitized with aluminium-containing allergen extracts. Allergy 1985;40:36872.
  • 262
    Garcia-Patos V, Pujol RM, Alomar A, et al. Persistent-subcutaneous nodules in patients hyposensitized with aluminum-containing allergen extracts. Arch Dermatol 1995;131:14214.
  • 263
    Phanuphak P, Kohler PE Onset of polyarteritis nodosa during allergic hyposensitization treatment. Am J Med 1980;68:47985.
  • 264
    Cabrera GE, Citera G, Gutierrez M, Scopelitis E, Espinoza LR. Digital vasculitis following allergic desensi-tization treatment. J Rheumatol 1993;20:19702.
  • 265
    Stewart GD, Lockey RE Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992;90:56778.
  • 266
    Greenberg MA, Kaufman CR, Gonzalez GE, Trusewych ZP, Rosenblatt CD, Summers RJ. Late systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol 1988;82:28790.
  • 267
    Tabar AI, Garcia BE, Rodriguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993;48:4503.
  • 268
    Hejjaoui A, Ferrando R, Dhivert H, Michel FB, Bousquet J. Systemic reactions occurring during immunotherapy with standardized pollen extracts J Allergy Clin Immunol 1992;89: 92533.
  • 269
    Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. III. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989;83: 797802.
  • 270
    Nelson BL, Dupont LA, Reid MJ. Prospective survey of local and systemic reactions to immunotherapy with pollen extracts. Ann Allergy 1986;56:3314.
  • 271
    Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 1990;85: 14739.
  • 272
    Portnoy J, Bagstad K, Kanarek H, Pacheco F, Hall B, Barnes C. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy 1994;73:40918.
  • 273
    Jarisch R, Gotz M, Aberer W, et al. Reduction of side effects of specific imrnunotherapy by premedication with antihistaminics and reduction of maximal dosage to 50000 SQ-U/ml. Arb Paul Ehrlich Inst Bundesamt Sera Impf-stoffe Frankf A M 1988;82:16375.
  • 274
    Nielsen L, Johnsen C, Mosbech H, Poulsen L, Malling H. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1996;97:120713.
  • 275
    Berchtold E, Maibach R, Müller U. Reduction of side effects from rush-immunotherapy with honeybee venom by pretreatment with terfenadine. Clin Exp Allergy 1992; 225965.
  • 276
    Østerballe O. Side effects during immunotherapy with purified grass pollen extracts. Allergy 1982;37:55362.
  • 277
    Lessof M, Chandler B. Experience with Spectralgen/ Pharmalgen a new kind of allergen preparation. Amsterdam: Excerpta Medica, 1983.
  • 278
    Lockey RF, Nrkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC. The Hymenoptera venom study. III. Safety of venom immunotherapy. J Allergy Clin Immunol 1990;86: 77580.
  • 279
    Müller U, Lanner A, Schmid P, Bischof M, Dreborg S, Hoigne R. A double blind study on immunotherapy with chemically modified honeybee venom: monomethoxy polyethylene glycol-coupled versus crude honeybee venom. Int Arch Allergy Appl Immunol 1985;77:2013.
  • 280
    Nataf P, Guinnepain MT, Herman D. Rush venom immunotherapy: a 3-day programme for Hymenoptera sting allergy. Clin Allergy 1984;14:26975.
  • 281
    Bernstein DI, Mittman RJ, Kagen SL, Korbee L, Enrione M, Bernstein IL. Clinical and immunologic studies of rapid venom immunotherapy in Hymenoptera-sensitive patients. J Allergy Clin Immunol 1989;84:9519.
  • 282
    Malling H-J, Djurup R, Sondergaard I, Weeke B. Clustered immunotherapy with yellow jacket venom. Evaluation of the influence of time interval on in vivo and in vitro parameters. Allergy 1985;40: 37383.
  • 283
    Bousquet J, Demoly P, Michel FB. Specific imrnunotherapy. In: BarnesPJ, GrunsteinMM, LeffAR, WoolcockAJ, editors. Asthma. Philadelphia: Lippincott-Raven, 1997: 166782.
  • 284
    Committee on Safety of Medicines. Desensitizing vaccines. BMJ 1986;293:948.
  • 285
    Lockey W, Benedict LM, Tbrkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987;79:66077.
  • 286
    Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TAE. Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol 1993;92615.
  • 287
    Reid M, Lockey R, Turkeltaub R, Platts-Mills TAE. Fatalities (F) from immunotherapy (IT), 1990–91 [abstract]. J Allergy Clin Immunol 1992;89:100.
  • 288
    Turkeltaub P. FDA Medical Bulletin 1994;7:May.
  • 289
    Lüderitz-Püchel U, May S, Haustein D. Zwischenfälle nach Hyposensibilisierung. Munch Med Wochenschr 1996;138: 12932.
  • 290
    Norman PS. Safety of allergen immunotherapy. J Allergy Clin Immunol 1989;84:4389.
  • 291
    American Academy of Allergy and Immunology. The waiting period after allergen skin testing and immunotherapy. J Allergy Clin Immunol 1990;85:5267.
  • 292
    Müller U, Mosbech H, Blaauw P, et al. Emergency treatment of allergic reactions to Hymenoptera stings. Clin Exp Allergy 1991;21:2818.
  • 293
    Müller U, Mosbech H, Aberer W, et al. Adrenaline for emergency kits. Allergy 1995;50:7837.
  • 294
    Practice parameters for allergen immunotherapy. Joint Task Force on Practice Parameters (American Academy of Allergy, Asthma, and Immunology, the American College of Allergy, Asthma, and Immunology, the Joint Council of Allergy, Asthma, and Immunology). J Allergy Clin Immunol 1996;98:100111.
  • 295
    Cooper PJ, Darbyshire J, Nunn AJ, Warner JO. A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children. Clin Allergy 1984;14:54150.
  • 296
    Taudorf E, Laursen LC, Djurup R, et al. Oral administration of grass pollen to hay fever patients An efficacy study in oral hyposensitization. Allergy 1985;40:32135.
  • 297
    Mosbech H, Dreborg S, Madsen F, et al. High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo-controlled study. Allergy 1987;42: 4515.
  • 298
    Oppenheimer J, Areson JG, Nelson HS. Safety and efficacy of oral imrnunotherapy with standardized cat extract. J Allergy Clin Immunol 1994;93:617.
  • 299
    Möller C, Dreborg S, Lanner A, Björkstén B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy 1986;41: 2719.
  • 300
    Giovane AL, Bardare M, Passalacqua G, et al. A three-year double-blind placebo-controlled study with specific ral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin Exp Allergy 1994;24:539.
  • 301
    Taudorf E, Laursen LC, Lanner A, et al. Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol 1987;80:15361.
  • 302
    Scadding G, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986;16:4939.
  • 303
    Reilly D, Taylor M, Beattie N, et al. Is evidence for homeopathy reproducible Lancet 1994;344:16016.
  • 304
    Van Niekerk CH, de Wet JI. Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay fever: a double-blind study. Clin Allergy 1987;17:50713.
  • 305
    Feliziani V, Marfisi RM, Parmiani S. Rush immunotherapy with sublingual administration of grass allergen extract. Allergol Immunopathol (Madr) 1993;21:1738.
  • 306
    Casanovas M, Guerra F, Moreno C, Miguel R, Maranon F, Daza JC. Double-blind, placebo-controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually. J Investig Allergol Clin Immunol 1994;4:30514.
  • 307
    Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr) 1995;23: 22430.
  • 308
    Sabbah A, Hassoun S, Le Sellin J, AndrB C, Sicard H. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:30913.
  • 309
    Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990;18: 27784.
  • 310
    Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. J Investig Allergol Clin Immunol 1995;5:2530.
  • 311
    Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993;92:22936.
  • 312
    Georgitis JW, Nickelsen JA, Wypych JI, Kane JH, Reisman RE. Local nasal immunotherapy: efficacy of low-dose aqueous ragweed extract. J Allergy Clin Immunol 1985;75:496500.
  • 313
    Georgitis JW, Nickelsen JA, Wypych JI, Barde SH, Clayton WF, Reisman RE. Local intranasal immunotherapy with high-dose polymerized ragweed extract. Int Arch Allergy Appl Immunol 1986;81:1703.
  • 314
    Welsh PW, Butterfield JH, Yunginger JW, Agarwal MK, Gleich GJ. Allergen-controlled study of intranasal immunotherapy for ragweed hay fever. J Allergy Clin Immunol 1983;71:45460.
  • 315
    Ariano R, Panzani RC, Chiapella M, Augeri G, Falagiani E Local intranasal immunotherapy with allergen in powder in atopic patients sensitive to Parietaria officinalis pollen. J Investig Allergol Clin Immunol 1995;5:12632.
  • 316
    Andri L, Senna GE, Betteli C, et al. Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study. Allergy 1992;47: 31823.
  • 317
    Andri L, Senna G, Betteli C, Givanni S, Andri G, Falagiani P. Local nasal immunotherapy for Dermato-phagoides-induced rhinitis: efficacy of a powder extract. J Allergy Clin Immunol 1993;91:98796.
  • 318
    Andri L, Senna G, Andri G, et al. Local nasal immunotherapy for birch allergic rhinitis with extract in powder form. Clin Exp Allergy 1995;25:10929.
  • 319
    Andri L, Senna G, Betteli C, et al. Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study. J Allergy Clin Immunol 1996;97:3441.
  • 320
    Bardare M, Zani G, Novembre E, Vierucci A. Local nasal immunotherapy with a powdered extract for grass pollen induced rhinitis in pediatric age. J Investig Allergol Clin Immunol 1996;6:35963.
  • 321
    Cirla AM, Sforza N, Roffi GP, et al. Preseasonal intranasal immunotherapy in birch-alder allergic rhinitis A double-blind study. Allergy 1996;51:299306.
  • 322
    D'Amato G, Lobefalo G, Liccardi G, Cazzola M. A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. Clin Exp Allergy 1995;25:1418.
  • 323
    Georgitis JW, Reisman RE, Clayton WF, Muller UR, Wypych JI, Arbesman CE. Local intranasal immunotherapy for grass-allergic rhinitis. J Allergy Clin Immunol 1983;71:716.
  • 324
    Georgitis JW, Clayton WF, Wypych JI, Barde SH, Reisman RE. Further evaluation of local intranasal immunotherapy with aqueous and allergoid grass extracts. J Allergy Clin Immunol 1984;74:694700.
  • 325
    Johansson SG, Deuschl H, Zetterström O. Use of glutaraldehyde-modified timothy grass pollen extract in nasal hyposensitization treatment of hay fever. Int Arch Allergy Appl Immunol 1979;60:44760.
  • 326
    Nickelsen JA, Goldstein S, Muller U, Wypych J, Reisman RE, Arbesman CE. Local intranasal immunotherapy for ragweed allergic rhinitis. 11. Immunologic response. J Allergy Clin Immunol 1981;68: 415.
  • 327
    Passalacqua G, Albano M, Ruffoni S, et al. Nasal immunotherapy to Purietaria: evidence of reduction of local allergic inflammation. Am J Respir Crit Care Med 1995;1521:4616.
  • 328
    Schumacher MJ, Pain MC. Intranasal immunotherapy and polymerized grass pollen allergens. Allergy 1982;37:2418.
  • 329
    Welsh PW, Zimmermann EM, Yunginger JW, Kern EB, Gleich GJ. Preseasonal intranasal immunotherapy with nebulized short ragweed extract. J Allergy Clin Immunol 1981;67:23742.
  • 330
    Bjorkstn B. Local immunotherapy is not documented for clinical use. Allergy 1994;49:299301.
  • 331
    Crimi E, Voltolini S, Troise C, et al. Local immunotherapy with Dermatophagoides extract in asthma. J Allergy Clin Immunol 1991;87: 7218.
  • 332
    Tari MG, Mancino M, Monti G. Immunotherapy by inhalation of allergen in powder in house dust allergic asthma - a double-blind study. J Investig Allergol Clin Immunol 1992;2:5967.
  • 333
    Ownby DR, Adinoff AD. The appropriate use of skin testing and allergen immunotherapy in young children. J Allergy Clin Immunol 1994;94:6625.
  • 334
    Jacobsen L. The benefit of specific allergy treatment. In: BasombaA, SastreJ, editors. Proceedings of the XVI European Congress of Allergology and Clinical Immunology. Bologna, Italy: Monduzzi Editore, 1995: 74550.
  • 335
    Jacobsen L, Dreborg S, MQller C, et al. Immunotherapy as a preventive treatment [Abstract]. J Allergy Clin Immunol 1996;97:232.
  • 336
    Des Roches A, Paradis L, Knani J, Hejjaoui A, Dhivert H, Michel F. Specific immunotherapy prevents the onset of new sensitizations in monosensitized children [Abstract]. J Allergy Clin Immunol 1995;95:309.
  • 337
    Barnard J. Studies of 400 Hymenoptera sting deaths. J Allergy Clin Immunol 1973;52:25964.
  • 338
    Ownby DR, Adinoff AD. The appropriate use of skin testing and allergen immunotherapy in young children. J Allergy Clin Immunol 1994;94:6625.
  • 339
    Perrin JM, MacLean W Jr, Perrin EC. Parental perceptions of health status and psychologic adjustment of children with asthma. Pediatrics 1989;83:2630.
  • 340
    Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992;90:25662.
  • 341
    Sampson HA. Food allergy and the role of immunotherapy. J Allergy Cli Immunol 1992;90: 1512.
  • 342
    Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992;22:4406.
  • 343
    Leroy B, Lachapelle JM, Jacquemin MG, Saint-Remy JM. Immunotherapy of atopic dermatitis by injections of antigen-antibody complexes. Dermatology 1993;186:2767.
  • 344
    Kaplan AP, Anderson JA, Valentine MD, et al. Beta-adrenergic blockers, immunotherapy, and skin testing. American Academy of Allergy and Immunology. J Allergy Clin Immunol 1989;84: 12930.
  • 345
    Schwartz HJ, Golden DB, Lockey RE Venom immuno therapy in the Hymenoptera-allergic pregnant patient. J Allergy Clin Immunol 1990;85:70912.
  • 346
    Schumacher MJ, Tveten MS, Egen NB. Rate and quantity of delivery of venom from honeybee stings. J Allergy Clin Immunol 1994;93:8315.
  • 347
    Golden DB, Valentine MD, Kagey-Sobotka A, Lichten-stein LM. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980;92:6204.
  • 348
    Reisman RE, Livingston A. Venom immunotherapy: 10 years of experience with administration of single venoms and 50 micrograms maintenance doses. J Allergy Clin Immunol 1992;89:118995.
  • 349
    Bousquet J, Menardo JL, Aznar R, Robinet-Levy M, Michel FB. Clinical and immunologic survey in beekeepers in relation to their sensitization. J Allergy Clin Immunol 1984;73:33240.
  • 350
    Bousquet J, Menardo JL, Velasquez G, Michel FB. Systemic reactions during maintenance immunotherapy with honeybee venom. Ann Allergy 1988;61:638.
  • 351
    Kampelmacher MJ, van der Zwan JC. Provocation test with a living insect as a diagnostic tool in systemic reactions to bee and wasp venom: a prospective study with emphasis on the clinical aspects. Clin Allergy 1987;17:31727.
  • 352
    van Halteren HK, van der Linden PW, Burgers SA, Bartelink AK. Hymenoptera sting challenge of 348 patients: relation to subsequent field stings. J Allergy Clin Immunol 1996;97:105863.
  • 353
    Blaauw PJ, Smithuis OL, Elbers AR. The value of an in-hospital insect sting challenge as a criterion for application or omission of venom immunotherapy. J Allergy Clin Immunol 1996;98:3947.
  • 354
    Franken HH, Dubois AE, Minkema HJ, van der Heide S, de Monchy JG. Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hyper-sensitivity. J Allergy Clin Immunol 1994;93:4316.
  • 355
    Rueff F, Przybilla B, Miiller U, Mosbech H. The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom of the European Academy of Allergology and Clinical Immunology. Allergy 1996;51: 21625.
  • 356
    Nordvall SL, Johansson SG, Ledford DK, Lockey RE Allergens of the imported fire ant. J Allergy Clin Immunol 1988;82:56776.
  • 357
    Norman P. Is there a role for immunotherapy in the treatment of asthma? Yes. Am J Respir Crit Care Med 1996;154:12258.
  • 358
    Barnes P Is there a role for immunotherapy in the treatment of asthma? No. Am J Respir Crit Care Med 1996;154:12278.
  • 359
    Bousquet J, Dhivert H, Michel FB. Current trends in the management of allergic diseases. Allergy 1994;49:316.
  • 360
    Bush R, Huftel M, Busse W. Patient selection. In. LockeyR, BukantzS, editors. Allergen immunotherapy. New York: Marcel Dekker, 1991: 2549.
  • 361
    Platts-Mills TAE, Vervloet D, Thomas W, Aalberse R, Chapman M. Report of the Third International Workshop on Indoor Allergens and Asthma. J Allergy Clin Immunol 1998;100:S1S25.
  • 362
    Reed CE, Yunginger JW, Evans R. Quality assurance and standardization of allergy extracts in allergy practice. J Allergy Clin Immunol 1989;8:448.
  • 363
    Position paper on allergen immunotherapy. Report of a BSACI working party. January-October 1992. Clin Exp Allergy 1993;3: 144.
  • 364
    Munir AKM, Björkstén B, Einarsson R, et al. Cat (Fel d I), dog (Can f I), and cockroach allergens in homes of asthmatic children from three climatic zones in Sweden. Allergy 1994;49:50816.
  • 365
    Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992;326:8626.
  • 366
    Adelroth E, Rosenhall L, Glennow C. High dose inhaled budesonide in the treatment of severe steroid-dependent asthmatics. A two-year study. Allergy 1985;40: 5864.
  • 367
    Rutten van Molken MP, Van Doorslaer EK, Jansen MC, Kerstjens HA, Rutten FE Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;151:97582.
  • 368
    Weiss K. The impact of pharmacologic therapy on the costs of asthma. Allergy Proc 1994;15:18992.
  • 369
    Hughes DM, McLeod M, Garner B, Goldbloom RB. Controlled trial of a home and ambulatory program for asthmatic children. Pediatrics 1991;87:5461.
  • 370
    Mayo PH, Richman J, Harris HW. Results of a program to reduce admissions for adult asthma. Ann Intern Med 1990;112:86471.
  • 371
    Ross RN, Morris M, Sakowitz SR, Berman BA. Cost-effectiveness of including cromolyn sodium in the treatment program for asthma: a retrospective, record-based study. Clin Ther 1988;10:188203.
  • 372
    Mahr TA, Evans RD. Allergist influence on asthma care. Ann Allergy 1993;71:11520.
  • 373
    Doan T, Grammer LC, Yarnold PR, Greenberger PA, Patterson R. An intervention program to reduce the hospitalization cost of asthmatic patients requiring intubation. Ann Allergy Asthma Immunol 1996;76:51318.
  • 374
    Storms B, Olden L, Nathan R, Bodman S. Effect of allergy specialist care on the quality of life in patients with asthma. Ann Allergy Asthma Immunol 1995;75:4914.
  • 375
    Sullivan T, Selner J, Patterson R, Portnoy J, Seligmanqh M. Expert care and immunotherapy for asthma. A review of published studies with emphasis on patient outcome and cost. American College of Allergy, Asthma, and Immunology, 1996.
  • 376
    Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994;94: 1828.
  • 377
    Liblau RS, Singer SM, McDevitt HO. Thl and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:348.
  • 378
    Rapoport MJ, Jaramillo A, Zipris D, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993;178:8799.
  • 379
    Lenschow DJ, Walunas TL, Bluestone JA. CD28B7 system of T cell costimulation. Annu Rev Immunol 1996;14:23358.
  • 380
    Kuchroo VK, Das MP, Brown JA, et al. B7–1 and B7–2 costimulatory molecules activate differentially the Thl/ Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:70718.
  • 381
    Singh RR, Hahn BH, Sercarz EE. Neonatal peptide exposure can prime T cells and, upon subsequent immunization, induce their immune deviation: implications for antibody vs. T cell-mediated autoimmunity. J Exp Med 1996;183: 161321.
  • 382
    Genain CP, Abel K, Belmar N, et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996;274:20547.
  • 383
    Blanas E, Carbone FR, Allison J, Miller JF, Heath WR. Induction of autoimmune diabetes by oral administration of autoantigen. Science 1996;2741:7079.
  • 384
    Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993;259:13214.
  • 385
    Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993;261:172730.
  • 386
    Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 1993;341:9278.
  • 387
    Valenta R, Kraft D. Recombinant allergens for diagnosis and therapy of allergic diseases. Curr Opin Immunol 1995;7:7516.
  • 388
    Anderson P. Delivery systems for immunomodulatory proteins and peptides. BioDrugs 1997;7:5165.
  • 389
    McWilliam AS, Stewart GA. Production of multilamellar, small unilamellar and reverse-phase liposomes containing house dust mite allergens. Potential adjuvants in the immunotherapy of allergic disease. J Immunol Methods 1989;121: 5360.
  • 390
    Ferreira F, Hirthenlehner K, Briza P, et al. Isoforms of atopic allergens with reduced allergenicity but conserved T cell antigenicity: possible use for specific immunotherapy. Int Arch Allergy Immunol 1997;113:1257.
  • 391
    Ferreira F, Hirtenlehner K, Jilek A, et al. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 1996;183:599609.
  • 392
    Smith AM, Chapman MD. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol Immunol 1996;33:399405.
  • 393
    Noguchi E, Shibasaki M, Nishiyama C, Okumura Y, Takita H. IgE responsiveness to Dermatophagoides farinae in young asthmatic children: IgE binding study using recombinant allergens of Der f 1, Der f 2 and mutant proteins of Der f 2. Int Arch Allergy Immunol 1996;110:3807.
  • 394
    Vrtala S, Hirtenlehner K, Vangelista L, et al. Conversion of the major birch pollen allergen, Bet v 1, into two non-anaphylactic T cell epitope-containing fragments; candidates for a novel form of irnmunotherapy. J Clin Invest 1997;99:167381.
  • 395
    Yssel H, Fasler S, Lamb J, de Vries JE. Induction of non-responsiveness in human allergen-specific type 2 T helper cells. Curr Opin Immunol 1994;6:84752.
  • 396
    Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci U S A 1993;901: 760812.
  • 397
    Hoyne GF, Callow MG, Kuo MC, Thomas WR. Characterization of T-cell responses to the house dust mite allergen Der p II in mice. Evidence for major and cryptic epitopes. Immunology 1993;78: 6573.
  • 398
    Norman P, Ohman J Jr, Long A, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996;154:16238.
  • 399
    Ball T, Vrtala S, Sperr WR, et al. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem 1994;269: 283238.
  • 400
    Gajhede M, Osmark P, Poulsen F, et al. X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy. Nat Struct Biol 1996;3:10404.
  • 401
    Fedorov A, Ball T, Mahoney N, Valenta R, Almo S. Crystal structure and IgE-epitope mapping of birch pollen profilin: molecular basis for allergen cross-reactivity. Structure 1997;15:3345.
  • 402
    Donnelly JJ, Ulmer JB, Liu MA. DNA vaccines. Life Sci 1997;60:16372.
  • 403
    Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: a novel approach to immunization. Int J Immunopharmacol 1995;17:7983.
  • 404
    Raz E, Tighe H, Sato Y, et al. Preferential induction of a Tnl immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A 1996;93:51415.
  • 405
    Hsu CH, Chua KY, Tao MH, et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996;2:5404.
  • 406
    Lichtenstein L, Holtzman N, Burnett L. A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol 1968;101:31724.
  • 407
    Aalberse RC, van der Gaag R, Van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983;130: 7216.
  • 408
    Birkner T, Rumpold H, Jarolim E, et al. Evaluation of immunotherapy-induced changes in specific IgE, IgG and IgG subclasses in birch pollen allergic patients by means of immunoblotting. Correlation with clinical response. Allergy 1990;45: 41826.
  • 409
    Menz G, Dolecek C, Schonheit-Kenn U, et al. Serological and skin-test diagnosis of birch pollen allergy with recorn binant Bet v 1, the major birch pollen allergen. Clin Exp Allergy 1996;26:5060.
  • 410
    Pauli G, Oster JP, Deviller P, et al. Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies. J Allergy Clin lmmunol 1996;97:11009.
  • 411
    Vrtala S, Susani M, Sperr WR, et al. Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p 2, Phl p 5). J Allergy Clin Immunol 1996;97:7817.
  • 412
    Tame A, Sakiyama Y, Kobayashi I, Terai I, Kobayashi K. Differences in titres of IgE, IgG4 and other IgG subclass anti-Der p 2 antibodies in allergic and non-allergic patients measured with recombinant allergen. Clin Exp Allergy 1996;26:439.
  • 413
    Kobayashi I, Sakiyama Y, Tame A, Kobayashi K, Matsumoto S. IgE and IgG4 antibodies from patients with mite allergy recognize different epitopes of Dermatophagoides pteronyssinus group II antigen (Der p 2). J Allergy Clin Immunol 1996;97:63845.
  • 414
    Lebecque S, Dolecek C, Laffler S, et al. Immunologic characterization of monoclonal antibodies which modulate human immunoglobulin E binding to the major birch pollen allergen Bet v 1. J Allergy Clin Immunol 1997;99:37484.
  • 415
    Vassella CC, Odelram H, Kjellman NI, Borres MP, Vanto T, Björkstén B. High anti-IgE levels at birth are associated with a reduced allergy prevalence in infants at risk: a prospective study. Clin Exp Allergy 1994;24:7717.
  • 416
    Miescher S, Vogel M, Stampfli MR, et al. Domain-specific anti-IgE antibodies interfere with IgE binding to Fc epsilon RII. Int Arch Allergy Immunol 1994;105:7582.
  • 417
    Shakib F, Smith SJ. In vitro basophil histamine-releasing activity of circulating IgGl and IgG4 autoanti-IgE antibodies from asthma patients and the demonstration that anti-IgE modulates allergen-induced basophil activation. Clin Exp Allergy 1994;242:705.
  • 418
    Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994;269:2636873.
  • 419
    Fahy J, Fleming H, Wong H, et al. The effect of an anti-IgE monoclonal antibody on the early and late phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:182834.
  • 420
    Demoly P, Bousquet J. Anti-IgE therapy for asthma. Am J Respir Crit Care Med 1997;155:18257.
  • 421
    Hellman L. Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. Eur J Irnmunol 1994;24:41520.
  • 422
    Stadler B, Rudolf M, Vogel M, Mieser S, Ziircher A, Kricek F. Can active immunization redirect an anti-IgE immune response Int Arch Allergy Immunol 1997;113:21618.